These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19303654)

  • 1. Substituted imidazopyridines as potent inhibitors of HCV replication.
    Vliegen I; Paeshuyse J; De Burghgraeve T; Lehman LS; Paulson M; Shih IH; Mabery E; Boddeker N; De Clercq E; Reiser H; Oare D; Lee WA; Zhong W; Bondy S; Pürstinger G; Neyts J
    J Hepatol; 2009 May; 50(5):999-1009. PubMed ID: 19303654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and characterization of substituted diphenyl heterocyclic compounds as potent and selective inhibitors of hepatitis C virus replication.
    Huang P; Goff DA; Huang Q; Martinez A; Xu X; Crowder S; Issakani SD; Anderson E; Sheng N; Achacoso P; Yen A; Kinsella T; Darwish IS; Kolluri R; Hong H; Qu K; Stauffer E; Goldstein E; Singh R; Payan DG; Lu HH
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1419-29. PubMed ID: 18227176
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Ng TI; Tripathi R; Reisch T; Lu L; Middleton T; Hopkins TA; Pithawalla R; Irvin M; Dekhtyar T; Krishnan P; Schnell G; Beyer J; McDaniel KF; Ma J; Wang G; Jiang LJ; Or YS; Kempf D; Pilot-Matias T; Collins C
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activity.
    St Laurent DR; Serrano-Wu MH; Belema M; Ding M; Fang H; Gao M; Goodrich JT; Krause RG; Lemm JA; Liu M; Lopez OD; Nguyen VN; Nower PT; O'Boyle DR; Pearce BC; Romine JL; Valera L; Sun JH; Wang YK; Yang F; Yang X; Meanwell NA; Snyder LB
    J Med Chem; 2014 Mar; 57(5):1976-94. PubMed ID: 23573957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro.
    Paeshuyse J; Kaul A; De Clercq E; Rosenwirth B; Dumont JM; Scalfaro P; Bartenschlager R; Neyts J
    Hepatology; 2006 Apr; 43(4):761-70. PubMed ID: 16557546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
    Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
    Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of hepatitis C virus replication by semi-synthetic derivatives of glycopeptide antibiotics.
    Obeid S; Printsevskaya SS; Olsufyeva EN; Dallmeier K; Durantel D; Zoulim F; Preobrazhenskaya MN; Neyts J; Paeshuyse J
    J Antimicrob Chemother; 2011 Jun; 66(6):1287-94. PubMed ID: 21436155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent From Interferons.
    Laidlaw SM; Marukian S; Gilmore RH; Cashman SB; Nechyporuk-Zloy V; Rice CM; Dustin LB
    Gastroenterology; 2017 Aug; 153(2):566-578.e5. PubMed ID: 28456632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells.
    Lin K; Perni RB; Kwong AD; Lin C
    Antimicrob Agents Chemother; 2006 May; 50(5):1813-22. PubMed ID: 16641454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical characterization of the novel HCV NS3 protease inhibitor GS-9256.
    Yang H; Yang C; Wang Y; Rhodes G; Robinson M; Cheng G; Qi X; Mo H; Tian Y; Pakdaman R; Sheng XC; Kim CU; Delaney WE
    Antivir Ther; 2017; 22(5):413-420. PubMed ID: 28106531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
    Yu M; Corsa AC; Xu S; Peng B; Gong R; Lee YJ; Chan K; Mo H; Delaney W; Cheng G
    Antiviral Res; 2013 Nov; 100(2):439-45. PubMed ID: 24013001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.
    Gottwein JM; Scheel TK; Jensen TB; Ghanem L; Bukh J
    Gastroenterology; 2011 Sep; 141(3):1067-79. PubMed ID: 21699793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
    Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
    Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug.
    Feng JY; Cheng G; Perry J; Barauskas O; Xu Y; Fenaux M; Eng S; Tirunagari N; Peng B; Yu M; Tian Y; Lee YJ; Stepan G; Lagpacan LL; Jin D; Hung M; Ku KS; Han B; Kitrinos K; Perron M; Birkus G; Wong KA; Zhong W; Kim CU; Carey A; Cho A; Ray AS
    Antimicrob Agents Chemother; 2014; 58(4):1930-42. PubMed ID: 24419349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.
    Okuse C; Rinaudo JA; Farrar K; Wells F; Korba BE
    Antiviral Res; 2005 Jan; 65(1):23-34. PubMed ID: 15652968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hairpin ribozymes in combination with siRNAs against highly conserved hepatitis C virus sequence inhibit RNA replication and protein translation from hepatitis C virus subgenomic replicons.
    Jarczak D; Korf M; Beger C; Manns MP; Krüger M
    FEBS J; 2005 Nov; 272(22):5910-22. PubMed ID: 16279954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A serine palmitoyltransferase inhibitor blocks hepatitis C virus replication in human hepatocytes.
    Katsume A; Tokunaga Y; Hirata Y; Munakata T; Saito M; Hayashi H; Okamoto K; Ohmori Y; Kusanagi I; Fujiwara S; Tsukuda T; Aoki Y; Klumpp K; Tsukiyama-Kohara K; El-Gohary A; Sudoh M; Kohara M
    Gastroenterology; 2013 Oct; 145(4):865-73. PubMed ID: 23791700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replication studies using genotype 1a subgenomic hepatitis C virus replicons.
    Gu B; Gates AT; Isken O; Behrens SE; Sarisky RT
    J Virol; 2003 May; 77(9):5352-9. PubMed ID: 12692237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of short RNA structural analogues against hepatitis C virus genotypes 2, 3 and 4 in replicon cells.
    Elshaffei IM; Gupta N; Wu CH; Wu DC; Hammad LN; Abo-Elmatty DM; Mesbah NM; Wu GY
    J Dig Dis; 2015 Aug; 16(8):449-55. PubMed ID: 25873200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication.
    Borawski J; Troke P; Puyang X; Gibaja V; Zhao S; Mickanin C; Leighton-Davies J; Wilson CJ; Myer V; Cornellataracido I; Baryza J; Tallarico J; Joberty G; Bantscheff M; Schirle M; Bouwmeester T; Mathy JE; Lin K; Compton T; Labow M; Wiedmann B; Gaither LA
    J Virol; 2009 Oct; 83(19):10058-74. PubMed ID: 19605471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.